On May 19, 2020, Innovation Pharmaceuticals Inc. issued a press release titled, Innovation Pharmaceuticals’ Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility; Demonstrates Potent and Rapid Virucidal Activity.
On May 21, 2020, Innovation Pharmaceuticals Inc. issued a shareholder alert titled, Pursuing the Gold Standard in the Battle Against SARS-CoV-2 (Covid-19).
Copies of the press release and alert are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively. The information in this Current Report on Form 8-K under Item 7.01, including the accompanying press release and alert, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by reference to such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press release dated May 19, 2020
99.2
Shareholder alert dated May 21, 2020
Market Data 
Markets 
AI
